Hospital costs of acute myocardial infarction in Hungary; 2003–2005

2007 ◽  
Vol 148 (27) ◽  
pp. 1259-1266 ◽  
Author(s):  
László Gulácsi ◽  
István Májer ◽  
Imre Boncz ◽  
Valentin Brodszky ◽  
Béla Merkely ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Disease Burden ◽  
Hospital Costs

Magyarországon jelentős az akut myocardialis infarctust szenvedett betegek száma, ezért elengedhetetlen a betegségteher (disease burden) pontosabb megismerése. Célkitűzés: Tanulmányunkban azt vizsgáljuk, hogy mekkora a finanszírozót érintő teher a hospitalizált, szívinfarktust szenvedett betegek esetén, az aktív és a krónikus kórházi ellátásban, valamint a járóbeteg- és az alapellátás területén, illetve felbecsüljük, hogy mekkora a társadalmat érintő indirekt költség. Módszer: Az Országos Egészségbiztosítási Pénztár adatbázisa alapján elemeztük az „új” infarktust szenvedett betegek aktív és krónikus kórházi ellátásának költségeit a 25 évnél idősebb populáció körében a 2003. májusi megbetegedést követő 12 és 24 hónapban. A betegeket nemek szerinti, és 25–44, 45–64, 65+ éves alcsoportokba osztottuk. Egyéb költségelemként figyelembe vettük a házi-, szakorvosi vizitek, betegszállítás, valamint a munkából való kiesés átlagköltségeit. Eredmények: Az akut myocardialis infarctus aktív kórházi ellátásának átlagos egészségbiztosítási költsége a megbetegedést követő 12 hónapban a nőknél általában magasabb, mint a férfiaknál: 476,3 ezer Ft vs 391,1 ezer Ft (65+ év); 429,1 Ft vs 389,4 ezer Ft (45–64 év) és 229,5 ezer Ft vs 240,6 ezer Ft (25–44 év). A krónikus ellátás terhe betegenként 15–40 ezer Ft az első évben, és az aktív ellátás költsége is hasonló nagyságrendű (22–54 ezer Ft/fő) az infarktus után 13–24 hónappal. Következtetések: Becslésünk szerint az évente közel 12 ezer hospitalizált infarktust szenvedett beteg direkt egészségügyi költségeire a biztosító 4,4 Mrd Ft-ot költött a betegséget követő első 12 hónapban, 3,6 Mrd Ft-ot aktív és 370 millió Ft-ot a krónikus kórházi ellátásban. Egy AMI elkerülésével 345–565 ezer Ft (kor és nem szerint különbözően) direkt egészségügyi költség takarítható meg az első 12 hónapban. Becslésünk szerint az AMI indirekt költsége a munkaképes korúak körében meghaladja a 840 millió Ft-ot egy évben (177 829 Ft/fő).

scholarly journals Association of proton pump inhibitor use with disease burden and cardiometabolic profile among patients hospitalized for acute myocardial infarction

2021 ◽  
Vol 16 (1-2) ◽  
pp. 5-5
Author(s):  
Admira Bilalić ◽  
Josip Anđelo Borovac ◽  
Tina Tičinović Kurir ◽  
Marko Kumrić ◽  
Andrija Matetić ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Disease Burden ◽  
Cardiometabolic Profile

Abstract 178: Acute Myocardial Infarction: Clinical Features and Performance Measures in Indigenous and Non-indigenous Australians

2015 ◽  
Vol 8 (suppl_2) ◽  
Author(s):  
Rosanna Tavella ◽  
Christopher Zeitz ◽  
Margaret Arstall ◽  
Derek Chew ◽  
Matthew Worthley ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Features ◽  
Performance Measures ◽  
Disease Burden ◽  
Bleeding Complications ◽  
Indigenous Australians ◽  
Hospital Outcomes ◽  
Risk Of Death ◽  
And Performance

Background: Ischemic heart disease is a major contributing factor to the significant mortality and disease burden gap for Indigenous Australians. The current study is a contemporary analysis of Indigenous and non-Indigenous acute myocardial infarction (AMI) patients in regards to clinical features, in-hospital outcomes and performance measures. Methods: All consecutive patients undergoing coronary angiography for AMI in South Australian public hospitals from January 2012 [[Unable to Display Character: &#8211;]] December 2013 were captured. AMI patients (as per Third Universal AMI Definition) were analyzed according to ethnicity (Indigenous/Non-Indigenous). Data was maintained by the Coronary Angiogram Database of South Australia (CADOSA), a comprehensive registry compatible with the NCDR ® CathPCI ® Registry. Results: From 10,469 coronary angiograms performed, the prevalence of Indigenous patients was 4%. The frequency of AMI was higher in Indigenous (n=212) vs. Non-Indigenous (n=3636) patients (50% vs. 36%, p <0.01), despite Indigenous patients being younger by 15 years (50±12 vs. 65±13, p<0.01) and also more likely to be female (41% vs. 29%, p<0.01). Age adjusted analyses revealed a higher prevalence of comorbidities in Indigenous patients including: smoker (66% vs. 34%, p<0.01), hypertension (70% vs. 64%, p<0.01), dyslipidaemia (71% vs. 59%, p<0.01), diabetes (58% vs. 29%, p<0.01), and prior AMI (26% vs. 20%, p<0.01). There were fewer ST elevation myocardial infarcts (STEMI) (33% vs. 39%, p<0.01) but higher rates of hospital transfers (43% 25%, p<0.01) amongst Indigenous patients. Percutaneous coronary intervention (PCI) was less frequently utilized in Indigenous patients (46% vs. 51%, p<0.01), including few Indigenous STEMI patients undergoing primary PCI (18% vs. 53%, <0.01). In-hospital outcomes were similar between Indigenous and non-Indigenous patients, including bleeding complications (0.9% vs. 1.5%, p>0.05) and mortality (2.5% vs. 2.9%, p>0.05), although the relative risk of death adjusted for comorbidities was higher among Indigenous patients (2.7, (0.8-8.0) vs. 0.4, (0.1-1.3,) p>0.05). Discharge therapies were mostly similar in Indigenous vs. non-Indigenous patients including aspirin (91% vs. 84%, p>0.05), beta-blockers (75% vs. 62%, p<0.01), statin (90% vs. 83%, p<0.01), ACE-inhibitor/angiotensin receptor blocker (81% vs. 78%, p>0.05), or referral to cardiac rehab (44% vs. 48%, p>0.05). Conclusion: Indigenous Australians present for angiography with AMI 15 years earlier than non-Indigenous Australians. Despite this, they have a greater incidence of comorbidities, are more often transferred but PCI is less often utilised. Although in-hospital complications do not differ, there is room for improvement given a higher risk of death. Furthermore, evaluation of medication compliance and access to medications post discharge may provide further insight into disease burden.

Abstract WP315: Acute Myocardial Infarction Associated With Worse Outcomes in Acute Cerebrovascular Disease

Stroke ◽  
2016 ◽  
Vol 47 (suppl_1) ◽  
Author(s):  
Sea mi Park ◽  
Shouri Lahiri ◽  
Asma Moheet ◽  
Jaspreet Mann ◽  
Axel Rosengart
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Cerebrovascular Disease ◽  
Hospital Stay ◽  
Early Recognition ◽  
Hospital Costs ◽  
Care Facility ◽  
Length Of Hospital Stay ◽  
Female Gender ◽  
Nationwide Inpatient Sample Database

Introduction/Hypothesis: We examined the prevalence and outcomes of patients admitted with acute cerebrovascular disease (ACVD) and concomitant acute myocardial infarction (AMI). Methods: We utilized the Healthcare Cost and Utilization Project Nationwide Inpatient Sample database (1998-2009) and identified 1,760,415 adult ACVD patients among 92,848,710 patients enrolled. Using SAS 6.4 and applying SPSS 22 the outcome variables mortality, length of hospital stay (LOS), hospital costs >$20,000, and disposition (home or any care facility) were selected and logistic regression analyses was performed adjusting for the covariates hypertension, diabetes mellitus, age, race, sex, number of comorbidities, and care complexity (numbers of inpatient procedures) among all ACVD with and without AMI. Results: Mean age was 71 years (SD 15) with 76% >65 years old; 54% female gender; 55% Whites, 11% Blacks, and 6% Hispanics. Among all ACVD, 66% had HTN, 28% DM, AMI 4.1%, LOS was 7.6 days (SD 9.8), in-patient mortality 12%; disposition home 42% and facility 44%, and mean hospital costs $36,010 (SD $63,331). After covariate adjustment, ACVD patients with AMI compared to those without AMI had a mortality of 30% vs 12% (P<0.000); LOS ≥7 days 53% vs 30% (P<0.000), facility discharge 68% vs 51% (P<0.000), and adjusted hospital costs 71% vs 44% (P<0.000). Conclusions: Acute myocardial infarction occurred in 4.1% of patients with acute cerebrovascular disease. It was associated with significantly increased risks of in-patient mortality, length of hospital stay, facility disposition and hospital costs. Considering the poor outcomes of ACVD patients with AMI may indicate more aggressive strategies for early recognition and reduction of myocardial injury.

scholarly journals PATIENT CLASSIFICATION AND HOSPITAL COSTS OF CARE FOR ACUTE MYOCARDIAL INFARCTION IN NINE EUROPEAN COUNTRIES

2012 ◽  
Vol 21 ◽  
pp. 19-29 ◽  
Author(s):  
Unto Häkkinen ◽  
Pietro Chiarello ◽  
Francesc Cots ◽  
Mikko Peltola ◽  
Hanna Rättö ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Hospital Costs ◽  
European Countries ◽  
Patient Classification ◽  
Costs Of Care

scholarly journals Recent US Patterns and Predictors of Prevalent Diabetes among Acute Myocardial Infarction Patients

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Bruce Ovbiagele ◽  
Daniela Markovic ◽  
Gregg C. Fonarow
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Time Trends ◽  
Clinical Characteristics ◽  
Disease Burden ◽  
Nationwide Inpatient Sample ◽  
Discharge Diagnosis ◽  
Vascular Risk ◽  
The Us

Background. Diabetes mellitus (DM) confers high vascular risk and is a growing national epidemic. We assessed clinical characteristics and prevalence of diagnosed DM among patients hospitalized with acute myocardial infarction (AMI) in the US over the last decade.Methods. Data were obtained from all states within the US that contributed to the Nationwide Inpatient Sample. All patients admitted to hospitals between 1997 and 2006 with a primary discharge diagnosis of AMI were included. Time trends in the proportion of these patients with DM diagnosis were computed.Results. The portion of patients with comorbid diabetes among AMI hospitalizations increased substantially from 18% in 1997 to 30% in 2006 (). Absolute numbers of AMI hospitalizations in the US decreased 8% (from 729, 412 to 672, 243), while absolute numbers of AMI hospitalizations with coexisting DM rose 51% ((131, 189 to 198, 044), both (). Women with AMI were significantly more likely to have DM than similarly aged men, but these differences diminished with increasing age.Conclusion. Although overall hospitalizations for AMI in the US diminished over the last decade, prevalence of diabetes rose substantially. This may have important consequences for the future societal vascular disease burden.

PP538 Burden Of Disease For Patients With Acute Myocardial Infarction Combining Dyslipidemia In China

2020 ◽  
Vol 36 (S1) ◽  
pp. 41-41
Author(s):  
Mengran Zhang ◽  
Hongchao Li ◽  
Aixia Ma ◽  
Pingyu Chen
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Disease Burden ◽  
Indirect Costs ◽  
Medical Costs ◽  
Chinese Patients ◽  
Direct Medical Costs ◽  
The Times ◽  
Serious Disease ◽  
High Hospitalization Cost

IntroductionPrevalence of dyslipidemia in Chinese adults is increasing rapidly. Dyslipidemia is one of the most important risk factors for acute myocardial infarction (AMI), which represents a serious disease burden to the country. However, there is no published research on the costs of Chinese patients diagnosed with AMI combining dyslipidemia. This study aimed to report key findings of the disease burden in China, including direct medical costs and direct non-medical costs.MethodsSix hospitals from different geographic areas were selected in China for data collection. Patients who were hospitalized due to AMI combining dyslipidemia from January 1 2016 to December 31 2016 in the six sites were enrolled. Direct medical costs including inpatient and outpatient costs were extracted through electronic medical records; medical costs occurred in other healthcare institutions and direct non-medical costs were collected by a face-to-face questionnaire survey. Results were analyzed with descriptive statistics.ResultsData of 900 patients were analyzed. There were more males (78.40%) than females. The mean age was 62.1 (SD: 11.5). The times of inpatient and outpatient per year were 0.57 and 8.67, respectively. Medium direct medical costs and medium direct non-medical costs were 31,440 RMB (Interquartile range (IQR): 21,533–48,202) (4,443 USD: 3043–6812) and 665 RMB (IQR: 351–1328) (94 USD: 50–188), respectively; while corresponding medium indirect costs per year were 659 RMB (IQR: 226–1579) (93 USD: 32–223).ConclusionsThis is the first study comprehensively analyzing the disease burden of patients diagnosed with AMI combining dyslipidemia in China. The results suggested that the medical cost of this population is still high. Hospitalization cost accounted for 81 percent of the total cost, which was around 1.3 times of the annual per capita disposable income over the same period. Therefore, the importance of providing effective clinical management as well as dyslipidemia prevention and control intervention should be highlighted, especially for middle-aged and elderly males with dyslipidemia.

scholarly journals Comparative treatment costs for patients with acute myocardial infarction between Finland and Norway

2019 ◽  
Vol 6 (2) ◽  
pp. 58-79
Author(s):  
Tor Iversen ◽  
Unto Häkkinen
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Mortality Rate ◽  
Low Income ◽  
Hospital Costs ◽  
Treatment Costs ◽  
First Year ◽  
Explanatory Variables ◽  
Comparative Treatment ◽  
One Year

Previous studies on patients with acute myocardial infarction have found that Finland has higher hospital costs per patient than Norway for the first hospital episode (HEP), while Norway has higher costs   during the first year after the initial admission. In this paper, we analyze the variation in treatment costs between Finland and Norway in detail by introducing novel explanatory variables. We find that the distance from the patient’s home to the hospital increases hospital costs at a declining scale and one-year hospital costs are higher for low-income patients. The higher one-year hospital costs in Norway are accompanied by a comparatively lower mortality rate. While for HEP, the introduction of new explanatory variables does not explain the greater costs in Finland compared with Norway, for one-year costs, the additional variables explain the greater one-year costs in Norway compared to Finland.Published: Online January 2019. In print January 2019.

Sign in / Sign up

Export Citation Format

Share Document